(Newswire.net — October 21, 2013) Stockton, CA —
STOCKTON, CALIFORNIA/October 21, 2013 / Newswire/ — Viratech Corp. (OTC: VIRA), has announced the rollout and launch of Cancer.im Version 2.0 Social Network Platform.
Viratech and its wholly owned subsidiaries have both licensed to and integrated various elements of their intellectual property into this new business platform of Cancer.im, which is a nonprofit foundation. Viratech will earn revenue from its development and operation of the cancer.im web site for Cancer.im by receiving a portion of donations to Cancer.im as compensation, and 100% of all advertising revenue generated from the site.
The Cancer.im vision is based on the Robert Ryan Cancer Protocol- a modular 15 part best practice guide on teaching and assisting cancer patients and their loved ones on the importance of Quality of Life and how to raise it when managing a diagnosis of cancer. To learn more, visit www.cancer.im.
“Today Cancer.im’s vision is now a reality, thanks to Viratech’s intellectual property toolset and integration team. We see this social network as having the potential to change the way people view and manage cancer,” states Dr. Kevin Buckman, CEO of Viratech.
In 2013, nearly 1.6 million Americans will be diagnosed with cancer. Of that, 581,000 people are expected to die. Cancer accounts for 1 in every 4 deaths, second only to heart disease as the most common cause of death. The monetary cost seems irrelevant to the loss of life. Overall costs of cancer are projected to exceed $201 billion in 2013: $77 billion for direct medical costs (all health expenditures) as well as over $124 billion for the indirect mortality costs.
One weapon on this war on cancer is Quality of Life (QoL). On October 27, 2007 Dr. Nikolaou, on behalf of Fox Chase Medical Center (a National Comprehensive Cancer Network) published a double blind placebo controlled study titled “Quality of Life (QOL) Supersedes the Classic Predictors of Survival in Locally Advanced Non-Small Cell Lung Cancer (NSCLC).” The study was designed to evaluate the role of QoL as a prediction for survival. Some 91 percent of patients completed a standardized QoL survey before treatment. All patients were followed for at least 17 months. What they found is quality of life emerged as the most significant predictor of overall patient survival.
“…We conducted two different statistical analyses including all the usual prognostic factors and either way, quality of life remained the strongest predictor of overall survival,”“…What’s more, if a patient’s quality of life increased over time, we saw a corresponding increase in survival,” said Dr. Benjamin Movsas of Henry Ford Hospital. This study concluded that by raising a Cancer Patients Quality of Life via the European Organization for Research and Treatment of Cancer QLQ-C30, you could directly lower the incidence of morbidity in a cancer patient, regardless of treatment.
Dr. Kevin Buckman, the CEO of Viratech states, “This is where Cancer.im is going to be a great service for cancer patients, and their friends and family by showing cancer patients that they can make a difference in their survival by researching, developing and executing a treatment plan. By giving them better control they can raise their statistical quantification of morbidity, while at the same time empowering their caregivers to teach them how to raise the QoL of their loved one. It is a transformation from helpless to helpful that can make a powerful difference.
Cancer.im’s new social network includes useful tools such as a powerful news engine, Micro-Social Networks (MSNs) and content management systems. It provides the tools needed for cancer patients to maintain a high Quality of Life and enables members to be organized, informed, and empowered survivors, as well as provide them with research that is being done on new solutions for early cancer detection and treatment. There are many other features for those involved with cancer, including referrals of researchers and health care providers.
Unlike other networks, Cancer.im was designed by a team that is dedicated to specifically serve the unique needs of cancer patients and its community in a new easy-to-use format.
Many more tools are being added to enhance the 15 Modules designed to decrease morbidity in cancer patients by increasing the Quality of Life. There is the “Save-it” button that allows someone browsing the web to click a button and add the content or submit “Write-it” requests for publication to a Writer or Researcher portal. The Q&A section allows members to ask and answer questions. The “i-Know” button allows for contribution of content to a private repository of information.
The Cancer.im business platform can be used with other diseases besides cancer. Viratech Corp., which owns an exclusive license for use of the platform within the biotech arena has already sublicensed this platform with two other biotech business entities, with plans to integrate this deeper into it licensing market.
About Viratech Corp and Cancer.im
Viratech Corp. has created the first open source biotech research social network platform. The purpose of the platform is to make it possible for individuals or smaller companies to compete with larger companies in the race to patent new medicines or technology.
Viratech’s subsidiary, Cancer.im, Inc., owns and operates http://cancer.im, a social network resource site for cancer patients, survivors, advocates and volunteers. Cancer.im harnesses social collaboration utilities to develop what Viratech believes will become the first experience-based search engine powered by social collaboration.
Forward-Looking Statements:
We caution that this forward-looking information is inherently uncertain and actual results may differ.
Contact: Dr. Kevin Buckman
Viratech, Corp.
http://viratech.org
Email Contact: info@viratech.org
209-477-3030